Key trends, including advancements in gene editing technologies with the introduction of CRISPR-Cas9, the development of personalized medicines, rising applications in agriculture and industrial processing, the surge of synthetic biology, and supportive government funding and incentives, will shape the biotech industry this year and beyond.
Given the industry tailwinds, it could be wise to invest in fundamentally sound biotech stocks United Therapeutics Corporation (UTHR), Puma Biotechnology, Inc. (PBYI), and Genmab A/S (GMAB) for future solid returns.
